Cardiovascular Catheters Market Outlook: Growth in Cases of Cardiovascular Diseases to Drive Market Growth to US$ 71.79 Billion by 2033

As per the latest market research by Business Market Insights (BMI), the research report "Cardiovascular Catheters Market Outlook Size and Forecast (2022–2033)" forecasts how the market is set to surge 117.3% by 2033 as rise in cases of cardiovascular diseases reshapes the cardiovascular catheters ecosystem. The report highlights technological advancements in drug-eluting balloons, and bioabsorbable catheters, revolutionizing the global landscape of cardiovascular catheters.

The report forecasts the market to expand from US$ 33.03 billion in 2024 to US$ 71.79 billion by 2033, registering a robust CAGR of 9.01% over the 2025–2033 period.

As​‍​‌‍​‍‌​‍​‌‍​‍‌ a result of technological changes in drug-eluting balloons and bioabsorbable catheters, the worldwide market for cardiovascular catheters is radically changing to the extent that treatment is becoming more effective and patient outcomes are improving over the long term. Drug-eluting balloons are equipped with a delivery mechanism for the release of therapeutic agents, e.g., antiproliferative drugs, directly to the vessel wall in angioplasty procedures. The local drug delivery inhibits restenosis without the necessity of a permanent implant thus, drug-eluting balloons make up the most viable alternative of traditional stents in specific clinical scenarios. Their application expansion in the treatment of peripheral and coronary artery disease is the major factor behind the rise of catheter-based therapies of the advanced type. In the same vein, bioabsorbable catheters along with the related devices constitute a radical change in cardiovascular care. The components of these catheters are such that they melt down and are absorbed by the body after the therapeutic function is done hence, there are no long-term problems resulting from permanent implants. Bioabsorbable techniques alleviate issues of chronic inflammation, late thrombosis, and the necessity of repeat interventions; thus, they facilitate the establishment of safer treatment regimens and more patient-friendly approaches. The performance, flexibility, and biocompatibility of these catheters have also been further enhanced by the progress made in the field of materials science, polymer engineering, and coating technologies. Basically, the combination of these innovations with better imaging compatibility and precision delivery systems considerably extends the limits of minimally invasive cardiovascular procedures. Hence, drug-eluting balloons and bioabsorbable catheters are transforming practices of cardiovascular catheter worldwide and leading to continuous market ​‍​‌‍​‍‌​‍​‌‍​‍‌expansion. ​‍​‌‍​‍‌

Overview of report findings

Market Growth

The Cardiovascular Catheters Market is projected to grow from US$ 33.03 billion in 2024 to US$ 71.79 billion by 2033, registering a compound annual growth rate (CAGR) of 9.01% between 2025 and 2033.

The growth in the cases of cardiovascular diseases and increasing preference for minimally invasive cardiac surgeries are key factors propelling market growth. Advancements in drug-eluting balloons, and bioabsorbable catheters are transforming the landscape of cardiovascular catheters.

Growth in the Cases of Cardiovascular Diseases

The growth in the number of cardiovascular disease (CVD) cases is a major driver of the cardiovascular catheters market worldwide. Factors such as aging populations, sedentary lifestyles, unhealthy dietary habits, smoking, obesity, and rising prevalence of diabetes and hypertension have significantly increased the global burden of heart-related conditions. As cardiovascular diseases remain the leading cause of mortality globally, the demand for effective diagnostic and interventional solutions continues to rise, directly supporting the increased use of cardiovascular catheters. Cardiovascular catheters play a critical role in diagnosing and treating a wide range of heart conditions, including coronary artery disease, arrhythmias, and structural heart defects. Procedures such as coronary angiography, angioplasty, stent placement, and electrophysiology studies rely heavily on catheter-based technologies. The growing number of patients requiring these procedures has led hospitals and cardiac centers to expand their catheterization capabilities and invest in advanced catheter systems. Moreover, the increasing incidence of CVD among younger populations has intensified the need for early diagnosis and timely intervention, further boosting catheter utilization. Advances in catheter design, imaging integration, and therapeutic functionality have improved procedural safety and outcomes, making catheter-based interventions a preferred option. Consequently, the rising prevalence of cardiovascular diseases continues to drive sustained demand and growth in the cardiovascular catheters market.

Increasing Preference for Minimally Invasive Cardiac Surgeries

The increasing preference for minimally invasive cardiac surgeries is a key factor driving growth in the cardiovascular catheters market. Minimally invasive procedures, such as catheter-based angioplasty, electrophysiology studies, and transcatheter valve interventions, offer significant advantages over traditional open-heart surgeries. These procedures typically result in smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery times, making them highly attractive to both patients and healthcare providers. As patient awareness of these benefits continues to rise, demand for catheter-based cardiac interventions is growing steadily. From a clinical perspective, minimally invasive cardiac surgeries reduce the risk of post-operative complications and infections, particularly among elderly patients and those with multiple comorbidities. This has encouraged physicians to increasingly rely on advanced cardiovascular catheters for diagnosis, treatment, and monitoring of various heart conditions. Technological advancements, including improved catheter flexibility, enhanced imaging guidance, and drug-eluting capabilities, have further expanded the range and effectiveness of minimally invasive cardiac procedures. In addition, healthcare systems are promoting minimally invasive approaches to reduce overall treatment costs and optimize resource utilization. Shorter hospital stays and lower readmission rates align with value-based care models, strengthening the case for catheter-based interventions. As a result, hospitals and cardiac centers are investing in advanced catheter technologies, reinforcing the strong link between the rising adoption of minimally invasive cardiac surgeries and sustained growth of the cardiovascular catheters market.

Geographic Insights

North America represents the largest region in the cardiovascular catheters market due to its highly developed healthcare infrastructure, high incidence of cardiovascular diseases, and strong adoption of advanced medical technologies. The region benefits from favourable reimbursement policies, a large base of skilled interventional cardiologists, and high procedure volumes for minimally invasive cardiac interventions. In addition, the presence of major medical device manufacturers and continuous investments in research and development support rapid innovation and commercialization of advanced catheter technologies, including imaging-guided and drug-eluting catheters. Europe is the second-largest region in the cardiovascular catheters market, supported by well-established public healthcare systems and a growing elderly population that is more susceptible to cardiovascular conditions. Asia Pacific is the fastest-growing region in the cardiovascular catheters market, driven by rapid healthcare infrastructure development, rising healthcare spending, and increasing awareness of cardiovascular diseases. Large patient populations, expanding access to advanced cardiac care, growth in medical tourism, and cost-effective manufacturing in countries such as China and India are accelerating adoption, positioning Asia Pacific as a key growth engine for the market.

Market Segmentation

• Based on Product, the market is segmented into balloon catheter, diagnostic catheter, guiding catheter, ablation catheter, IVUS catheter, and others. The balloon catheter segment dominated the market in 2024.
• Based on Coating Type, the market is segmented into coated catheters, uncoated catheters. The coated catheters segment dominated the market in 2024.
• Based on Lumen, the market is segmented into single-lumen, multi-lumen. The multi-lumen segment dominated the market in 2024.

• Based on End User, the market is segmented into hospitals & clinics, ambulatory surgical centers, diagnostic imaging centers, and others. The hospitals & clinics dominated the market in 2024.

Competitive Strategy & Development

Key Players: The Cardiovascular Catheters Market is populated by several key players, each contributing to its growth and innovation. Some prominent players are:

1. Medtronic Plc
2. Boston Scientific Corp
3. Becton, Dickinson and Co
4. Teleflex Inc
5. B. Braun SE
6. Abbott Laboratories
7. Terumo Corp

Trending Topics: Smart catheter technologies and embedded sensors, AI-integrated catheter systems, Robotic-assisted catheter navigation, Minimally invasive cardiac procedures growth, Single-use catheter adoption and infection control, Advanced imaging-guided catheters (e.g., OCT/IVUS), Drug-eluting and bioabsorbable catheter materials, Catheter navigation precision improvements

Global Headlines

• " Boston Scientific Secures CE Mark for Farapoint Pulsed Field Ablation Catheter - In December 2025, Boston Scientific recently secured CE Mark approval for its Farapoint pulsed field ablation catheter, part of its Farapulse platform. This device is designed to treat atrial flutter using electrical fields rather than traditional radiofrequency or cryoablation, reducing collateral damage and improving patient safety. The approval strengthens Boston Scientific’s position in the European electrophysiology market, allowing hospitals to adopt safer and faster ablation procedures while intensifying competition with Medtronic and Johnson & Johnson."
• " Johnson & Johnson’s Biosense Webster Gains CE Mark for SMARTTOUCH SF Catheter - In January 2025, Johnson & Johnson’s Biosense Webster division gained CE Mark approval for its THERMOCOOL SMARTTOUCH SF catheter, which integrates contact force sensing and advanced irrigation technology to improve precision in atrial fibrillation ablation. This approval reinforces J&J’s leadership in electrophysiology, where Biosense Webster already holds a dominant market share. Supported by positive data from the SmartfIRE study, the catheter enhances treatment safety and efficacy, giving European hospitals access to a more advanced ablation tool and strengthening J&J’s competitive edge against Boston Scientific and Medtronic."

Conclusion

The cardiovascular catheters market is poised for sustained growth, driven by a convergence of clinical demand, technological innovation, and evolving healthcare delivery models. The rising prevalence of cardiovascular diseases, including coronary artery disease and arrhythmias, continues to create a strong and consistent need for diagnostic and interventional catheter-based procedures. This demand is further amplified by the growing adoption of minimally invasive cardiac interventions, which offer reduced recovery times, lower procedural risks, and improved patient outcomes compared to traditional surgical approaches. Technological advancements, particularly in drug-eluting and bioabsorbable catheter designs, are enhancing procedural efficacy while addressing long-term safety concerns, thereby strengthening clinician confidence and adoption rates. At the same time, the integration of robotics-assisted and AI-guided catheterization systems represents a transformative trend, enabling greater procedural precision, improved navigation, and better clinical decision-making in complex interventional cardiology cases. Despite these positive dynamics, the market faces notable restraints, including the risk of catheter-associated infections and procedural complications, which necessitate continuous innovation in catheter coatings, materials, and infection-control protocols. Looking ahead, significant opportunities lie in the expansion of cardiovascular catheter adoption across emerging markets, where improving healthcare infrastructure and increasing awareness of cardiovascular health are unlocking new growth avenues.